Combination treatment with vedolizumab and anti-TNF-α in inflammatory bowel disease: safety data

被引：0
|
作者：
Buer, L. [1 ,2 ]
Hoivik, M. L. [1 ]
Medhus, A. W. [1 ]
Moum, B. [1 ,2 ]
机构：
[1] Oslo Univ Hosp, Dept Gastroenterol, Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
来源：
JOURNAL OF CROHNS & COLITIS | 2017年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P514
引用
收藏
页码：S341 / S342
页数：2
相关论文
共 50 条
  • [21] Use and outcomes of anti-TNF-α therapy in pregnant women with inflammatory bowel disease (IBD)
    Bell, Sally
    Julsgaard, Mette
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 98 - 98
  • [22] Update on the mechanisms of action of anti-TNF-α antibodies and their clinical implications in inflammatory bowel disease
    Eder, Piotr
    Linke, Krzysztof
    Witowski, Janusz
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (10): : 772 - 780
  • [23] Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease
    Zhang, Cui
    Shu, Weigang
    Zhou, Guangxi
    Lin, Jian
    Chu, Feifei
    Wu, Huili
    Liu, Zhanju
    MEDIATORS OF INFLAMMATION, 2018, 2018
  • [24] Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease. A nationwide series
    Toussirot, Eric
    Houvenagel, Eric
    Goeb, Vincent
    Fouache, Damien
    Martin, Antoine
    Le Dantec, Philippe
    Dernis, Emmanuelle
    Wendling, Daniel
    Ansemant, Thiphaine
    Berthelot, Jean-Marie
    Bader-Meunier, Brigitte
    Kantelip, Bernadette
    JOINT BONE SPINE, 2012, 79 (05) : 457 - 463
  • [25] Anti-TNF-α Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases
    Tripodi, Armando
    Spina, Luisa
    Pisani, Laura Francesca
    Padovan, Lidia
    Cavallaro, Flaminia
    Chantarangkul, Veena
    Valsecchi, Carla
    Peyvandi, Flora
    Vecchi, Maurizio
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (12) : 1901 - 1908
  • [26] Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment
    Di Sabatino, Antonio
    Santilli, Francesca
    Guerci, Marco
    Simeone, Paola
    Ardizzone, Sandro
    Massari, Alessandro
    Giuffrida, Paolo
    Tripaldi, Romina
    Malara, Alessandro
    Liani, Rossella
    Gurini, Evelyn
    Aronico, Nicola
    Balduini, Alessandra
    Corazza, Gino Roberto
    Devi, Giovanni
    THROMBOSIS AND HAEMOSTASIS, 2016, 116 (03) : 486 - 495
  • [27] Efficacy of combination therapy with cyclosporin and vedolizumab in inflammatory bowel diseases refractory to anti-TNF agents
    Rutka, M.
    Szanto, K.
    Bor, R.
    Balint, A.
    Fabian, A.
    Molnar, T.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S375 - S375
  • [28] SAFETY OF VEDOLIZUMAB USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Shivashankar, Raina
    Ladd, Antonio H. Mendoza
    Grace, Rory
    Aberra, Faten
    Lichtenstein, Gary R.
    GASTROENTEROLOGY, 2017, 152 (05) : S585 - S585
  • [29] ANTI-TNF EFFICACY AFTER PRIMARY VEDOLIZUMAB FAILURE IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
    Dolinger, Michael
    Rolfes, Priya
    Phan, Becky
    Pan, Stephanie
    Dubinsky, Marla
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S71 - S72
  • [30] Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
    Plevris, N.
    Chuah, C. S.
    Allen, R. M.
    Arnott, I. D.
    Brennan, P. N.
    Chaudhary, S.
    Churchhouse, A. M. D.
    Din, S.
    Donoghue, E.
    Gaya, D. R.
    Groome, M.
    Jafferbhoy, H. M.
    Jenkinson, P. W.
    Lam, W. L.
    Lyons, M.
    Macdonald, J. C.
    MacMaster, M.
    Mowat, C.
    Naismith, G. D.
    Potts, L. F.
    Saffouri, E.
    Seenan, J. P.
    Sengupta, A.
    Shasi, P.
    Sutherland, D. I.
    Todd, J. A.
    Veryan, J.
    Watson, A. J. M.
    Watts, D. A.
    Jones, G. R.
    Lees, C. W.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 (09): : 1111 - 1120
12345